tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dynavax sees FY24 HEPLISAV-B revenue $268M

HEPLISAV-B achieved preliminary net product revenue of $268M for the full year 2024, an increase of 26% compared to $213M for the full year 2023. FY24 revenue consensus $276.94M

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1